2017 Fiscal Year Final Research Report
A basic study of a new therapy based on an integrated cancer immune-genomic analysis for ovarian cancer
| Project/Area Number |
16K15708
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Obstetrics and gynecology
|
|---|
| Research Institution | Kyoto University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
吉岡 弓子 京都大学, 医学研究科, 助教 (10402918)
安彦 郁 京都大学, 医学(系)研究科(研究院), その他 (20508246)
濱西 潤三 京都大学, 医学研究科, 講師 (80378736)
小西 郁生 京都大学, 医学研究科, 名誉教授 (90192062)
|
|---|
| Project Period (FY) |
2016-04-01 – 2018-03-31
|
| Keywords | 免疫ゲノミクス解析 / 機能ゲノム解析 / がん免疫機構 / Ｔ細胞解析 / 卵巣癌腹膜播種モデル / Ｂ７ファミリー / PＤ－１抗体 / ＰＤ－Ｌ１抗体 |
|---|
| Outline of Final Research Achievements |
Using an ovarian cancer surgical specimen, we analyzed the pathologic changes and performed a T cell analysis before and after treatment. We recognized a consistent correlation between the changes in the T cell immunity state and the curative effect. Furthermore, we also identified specific molecules of the B7 family as immunologic factors, by comparing the pathologic changes before and after treatment with anticancer drugs using a mouse model of ovarian cancer peritoneum dissemination. We recognized that co-cultivating T cells for ovarian cancer cells expressing each gene induced these targets showed immunosuppressive activity. In addition, the T cells were re-activated when we suppressed the B7 family expression and inhibited the expression using a neutralizing antibody. In our in vitro mouse model of ovarian cancer, we demonstrated immunosuppressive activity similar to that observed in vitro and confirmed the prolonged survival by inhibition experiments using its antibody.
|
| Free Research Field |
婦人科癌治療
|
